Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 7 studies | 27% ± 10% | |
epithelial cell | 7 studies | 38% ± 18% | |
respiratory goblet cell | 5 studies | 23% ± 5% | |
goblet cell | 4 studies | 23% ± 4% | |
secretory cell | 3 studies | 29% ± 10% | |
abnormal cell | 3 studies | 23% ± 3% | |
squamous epithelial cell | 3 studies | 39% ± 22% | |
basal cell | 3 studies | 34% ± 12% | |
retinal cone cell | 3 studies | 30% ± 8% | |
endothelial cell | 3 studies | 23% ± 7% | |
type I pneumocyte | 3 studies | 20% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 1300.98 | 180 / 180 | 100% | 250.53 | 430 / 430 |
uterus | 100% | 2076.90 | 170 / 170 | 100% | 92.59 | 458 / 459 |
liver | 100% | 5913.77 | 226 / 226 | 100% | 89.06 | 405 / 406 |
pancreas | 100% | 2710.63 | 328 / 328 | 99% | 63.81 | 177 / 178 |
prostate | 100% | 3008.18 | 245 / 245 | 99% | 64.78 | 499 / 502 |
esophagus | 100% | 3046.48 | 1444 / 1445 | 99% | 87.47 | 182 / 183 |
stomach | 100% | 3258.29 | 359 / 359 | 99% | 89.53 | 284 / 286 |
intestine | 100% | 3345.77 | 966 / 966 | 99% | 89.38 | 523 / 527 |
breast | 100% | 2083.86 | 459 / 459 | 99% | 80.79 | 1109 / 1118 |
thymus | 100% | 2648.42 | 653 / 653 | 99% | 61.18 | 598 / 605 |
adrenal gland | 100% | 2290.45 | 258 / 258 | 99% | 47.34 | 227 / 230 |
bladder | 100% | 2882.76 | 21 / 21 | 98% | 96.18 | 495 / 504 |
lung | 99% | 2065.01 | 574 / 578 | 97% | 57.76 | 1122 / 1155 |
skin | 100% | 2340.30 | 1809 / 1809 | 95% | 45.60 | 447 / 472 |
kidney | 100% | 3203.26 | 89 / 89 | 95% | 36.09 | 852 / 901 |
brain | 98% | 1492.37 | 2599 / 2642 | 68% | 16.88 | 476 / 705 |
eye | 0% | 0 | 0 / 0 | 100% | 59.50 | 80 / 80 |
tonsil | 0% | 0 | 0 / 0 | 100% | 53.33 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 286.38 | 1 / 1 |
muscle | 100% | 1775.83 | 801 / 803 | 0% | 0 | 0 / 0 |
heart | 100% | 2233.60 | 858 / 861 | 0% | 0 | 0 / 0 |
adipose | 100% | 1689.40 | 1199 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 1551.03 | 1328 / 1335 | 0% | 0 | 0 / 0 |
spleen | 98% | 1110.56 | 237 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 24% | 5.53 | 7 / 29 |
peripheral blood | 14% | 90.24 | 130 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030522 | Biological process | intracellular receptor signaling pathway |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0050965 | Biological process | detection of temperature stimulus involved in sensory perception of pain |
GO_0030154 | Biological process | cell differentiation |
GO_0048666 | Biological process | neuron development |
GO_0043153 | Biological process | entrainment of circadian clock by photoperiod |
GO_0048856 | Biological process | anatomical structure development |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0043565 | Molecular function | sequence-specific DNA binding |
GO_0004879 | Molecular function | nuclear receptor activity |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | NR2F6 |
Protein name | Nuclear receptor subfamily 2 group F member 6 Nuclear receptor subfamily 2, group F, member 6 Nuclear receptor subfamily 2 group F member 6 (V-erbA-related protein 2) (EAR-2) Nuclear receptor V-erbA-related |
Synonyms | EAR2 ERBAL2 |
Description | FUNCTION: Transcription factor predominantly involved in transcriptional repression. Binds to promoter/enhancer response elements that contain the imperfect 5'-AGGTCA-3' direct or inverted repeats with various spacings which are also recognized by other nuclear hormone receptors. Involved in modulation of hormonal responses. Represses transcriptional activity of the lutropin-choriogonadotropic hormone receptor/LHCGR gene, the renin/REN gene and the oxytocin-neurophysin/OXT gene. Represses the triiodothyronine-dependent and -independent transcriptional activity of the thyroid hormone receptor gene in a cell type-specific manner. The corepressing function towards thyroid hormone receptor beta/THRB involves at least in part the inhibition of THRB binding to triiodothyronine response elements (TREs) by NR2F6. Inhibits NFATC transcription factor DNA binding and subsequently its transcriptional activity. Acts as transcriptional repressor of IL-17 expression in Th-17 differentiated CD4(+) T cells and may be involved in induction and/or maintenance of peripheral immunological tolerance and autoimmunity. Involved in development of forebrain circadian clock; is required early in the development of the locus coeruleus (LC). . |
Accessions | ENST00000596878.1 ENST00000291442.4 M0R175 P10588 B6ZGU2 F1D8R3 |